Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma

Abstract Background Adrenocortical carcinoma (ACC) is a highly malignant urologic cancer and tends to metastasize. Although immune checkpoint inhibitors (ICIs) bring a glimmer of light to conquer ACC, only a fraction of patients have benefit from ICIs treatment. It is well known that tumor mutationa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fangshi Xu, Yibing Guan, Peng Zhang, Li Xue, Yubo Ma, Mei Gao, Tie Chong, Bin-Cheng Ren
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2022-05-01
Series:BMC Endocrine Disorders
Assuntos:
Tumor mutational burden
Adrenocortical carcinoma
Immune checkpoint inhibitors
Immune microenvironment
Prognosis
Acceso en liña:https://doi.org/10.1186/s12902-022-01017-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares